ADC Therapeutics (ADCT) Income from Continuing Operations (2020 - 2026)
ADC Therapeutics (ADCT) posted Income from Continuing Operations of 32968000.0 for Q1 2026, up 19.52% sequentially from 40966000.0 in Q3 2025, and up 14.6% YoY from 28769118.73 in Q1 2025.
ADC Therapeutics (ADCT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 32968000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 14.6% year-over-year to 32968000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 169182000.0 (down 3.0% YoY) and the FY2022 annual result came in at 152624000.0, up 33.84% from the prior year.
- Income from Continuing Operations climbed to 32968000.0 in Q1 2026 per ADCT's latest filing, from 40966000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16661000.0 in Q1 2022 and troughed at 64374000.0 in Q2 2022.
- A 5-year average of 42683000.0 and a median of 44505500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations soared 67.67% in 2022, then sank 256.68% in 2023.
- Over 5 years, Income from Continuing Operations stood at 18153000.0 in 2022, then sank by 149.56% to 45302000.0 in 2023, then rose by 3.52% to 43709000.0 in 2024, then advanced by 6.28% to 40966000.0 in 2025, then rose by 19.52% to 32968000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 32968000.0, 40966000.0, and 56646000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | -16.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.57 Mn |
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -56.65 Mn |
| Mar 31, 2025 | -38.60 Mn |
| Sep 30, 2024 | -43.71 Mn |
| Jun 30, 2024 | -35.95 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Sep 30, 2023 | -45.30 Mn |
| Jun 30, 2023 | -48.20 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -18.15 Mn |
| Sep 30, 2022 | -50.61 Mn |
| Jun 30, 2022 | -64.37 Mn |
| Mar 31, 2022 | -16.66 Mn |
| Dec 31, 2021 | -35.52 Mn |
| Sep 30, 2021 | -71.55 Mn |
| Jun 30, 2021 | -72.57 Mn |
| Mar 31, 2021 | -51.53 Mn |
| Dec 31, 2020 | -56.26 Mn |